Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years

(2017) W. Sandborn et al.   Journal of Crohns & Colitis

Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience

(2016) T. Billiet et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

(2016) Kimberly A. Harris et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab for the Treatment of Refractory Crohnʼs Disease

(2016) Sam Khorrami et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease

(2015) Benjamin Pariente et al.   GASTROENTEROLOGY

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

(2014) U. Kopylov et al.   Journal of Crohns & Colitis

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement

(2013) Eric Toussirot et al.   Patient Preference and Adherence

Development of the Crohnʼs disease digestive damage score, the Lémann score

(2010) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

(2010) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health

(2009) Laurent Peyrin-Biroulet et al.   INFLAMMATORY BOWEL DISEASES

Infliximab for Inflammatory Bowel Disease in Denmark 1999–2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality

(2008) Sarah Caspersen et al.   Clinical Gastroenterology and Hepatology

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

(2008) H Fidder et al.   GUT